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durations of 300 ns and 1.7 μs, pulse energy 120–200 μJ, ret-
inal spot size 200 μm. Because SRT lesions are invisible, FA 
was always performed 1 h after treatment to demonstrate 
laser outcome (5–8 single spots in the area of leakage). In 
cases where energy was too low, as indicated by missing FA 
leakage, energy was adjusted and the patient re-treated im-
mediately. Observation intervals were after 4 weeks and 3 
months. In case of nonimprovement of the disease after 3 
months, re-treatment was considered.  Results: Of 10 pa-
tients with active CSC that presents focal leakage in FA, 5 had 
completely resolved fluid after 4 weeks and all 10 after 3 
months. Mean visual acuity increased from 76.6 ETDRS let-
ters to 85.0 ETDRS letters 3 months after SRT. Chronic-recur-
rent CSC was characterized by less severe SRF at baseline in 
OCT and weaker leakage in FA than in acute types. Visual 
acuity changed from baseline 71.6 to 72.8 ETDRS letters after 
3 months. At this time, SRF was absent in 3 out of 16 patients 
(19%), FA leakage had come to a complete stop in 6 out of 
16 patients (38%). In 6 of the remaining chronic CSC patients, 
repeated SRT with higher pulse energy was considered be-
cause of persistent leakage activity. After the re-treatment, 
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 Abstract 
 Purpose: Selective retina therapy (SRT), the confined laser 
heating and destruction of retinal pigment epithelial cells, 
has been shown to treat acute types of central serous cho-
rioretinopathy (CSC) successfully without damaging the 
photoreceptors and thus avoiding laser-induced scotoma. 
However, a benefit of laser treatment for chronic forms of 
CSC is questionable. In this study, the efficacy of SRT by 
means of the previously used 1.7-μs and shorter 300-ns pulse 
duration was evaluated for both types of CSC, also consider-
ing re-treatment for nonresponders.  Material and Methods: 
In a two-center trial, 26 patients were treated with SRT for 
acute (n = 10) and chronic-recurrent CSC (n = 16). All patients 
presented with subretinal fluid (SRF) in OCT and leakage in 
fluorescein angiography (FA). SRT was performed using a 
prototype SRT laser system (frequency-doubled Q-switched 
Nd:YLF-laser, wavelength 527 nm) with adjustable pulse du-
ration. The following irradiation settings were used: a train 
of 30 laser pulses with a repetition rate of 100 Hz and pulse 
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SRF resolved completely in 5 patients (83.3%) after only 25 
days.  Conclusion: SRT showed promising results in treating 
acute CSC, but was less effective in chronic cases. Interest-
ingly, re-treatment resulted in enhanced fluid resolution and 
dry conditions after a considerably shorter time in most pa-
tients. Therefore, SRT including re-treatment if necessary 
might be a valuable CSC treatment alternative even in chron-
ic-recurrent cases.  © 2015 S. Karger AG, Basel 
 Introduction 
 Patients with central serous chorioretinopathy (CSC) 
complain of visual disturbances including metamor-
phopsia, central scotoma, reduced visual acuity and loss 
of contrast sensitivity  [1] . CSC is usually characterized by 
idiopathic central leakage points with an exudative de-
tachment of the neurosensory retina mostly in the macu-
lar area. Fluorescein angiography (FA) shows single or 
multifocal spots of fluorescein leakage at the level of the 
retinal pigment epithelium (RPE)  [2, 3] , indicating focal 
RPE defects. Indocyanine green angiography reveals cho-
roidal hyperpermeability at the location of RPE leakage 
 [4] . The main diagnostic and monitoring tool today is 
optical coherence tomography (OCT) that shows the 
amount of subretinal fluid (SRF) in acute cases. Resolu-
tion of modern OCT is sufficient to detect small RPE de-
tachments within the region of neurosensory detachment 
 [5, 6] . 
 CSC has a favorable prognosis because SRF resolves in 
many cases within short time periods. In these cases, no 
treatment would be necessary. However, CSC can be-
come chronic, and patients experience significant perma-
nent visual impairment caused by recurrent episodes of 
acute CSC, persistent SRF and/or RPE atrophy  [7] . Focal 
laser photocoagulation with continuous-wave lasers, such
as argon (514 nm) or frequency doubled Nd-YAG (532 
nm), is considered in cases without spontaneous fluid re-
sorption. Such laser photocoagulation damages the neu-
ral retina: RPE cells, where the laser light is initially ab-
sorbed, are damaged directly by heating of the intracel-
lular melanosomes, and the overlying photoreceptors are 
coagulated by heat diffusion. Subsequently, RPE bystand-
er cells migrate and proliferate to cover the laser defect 
and ultimately re-establish an intact barrier  [8–11] .
 Photocoagulation is not feasible in many cases of CSC 
since CSC usually affects the fovea and photoreceptor co-
agulation would lead to central laser scotoma. Selective 
destruction of RPE cells that improves metabolism and 
hydraulic conductivity at the chorioretinal junction while 
avoiding adverse effects to the neuroretina and to the 
photoreceptors may be a viable appropriate treatment 
option. Selective damage of RPE cells was first demon-
strated by Roider et al.  [12, 13] using 5-μs argon laser 
pulses at 514 nm with a repetition rate of 500 Hz. A train 
of short microsecond pulses generates high peak temper-
atures around the melanosomes leading to mechanical 
rupture of RPE cells, whereas sublethal temperature in-
crease at the photoreceptors avoids their coagulation and 
laser scotoma  [14] . 
 Due to the lack of tissue coagulation, the selective le-
sions are ophthalmoscopically invisible and can only be 
visualized by FA, where they manifest as focal leakage in 
the early postoperative phase  [14] . Selective destruction 
of RPE cells with sparing of photoreceptors was original-
ly demonstrated by histological examinations in rabbits 
 [12, 13, 15] . The first clinical trials, undertaken with a 
frequency-doubled Nd:YLF-laser (527 nm, 1.7-μs pulse 
duration, 100 pulses at 500 Hz and 30 pulses at 100 Hz), 
have proven the concept of selective RPE destruction and 
subsequent healing by RPE migration and proliferation; 
clinical improvement of different macular diseases was 
obtained, presumably due to enhanced metabolism at the 
chorioretinal junction and improved cellular RPE pump 
function  [13, 16] . This treatment was named ‘selective 
retina treatment’ (SRT); an overview of the methods, 
techniques, preclinical and clinical results is given in 
Brinkmann et al.  [17] .
 Thus, SRT seems to be an ideal treatment modality for 
CSC, especially if the RPE leak is located close to the fo-
vea. Roider and coworkers  [18] demonstrated a benefit of 
SRT in acute CSC by finding short SRF resolution times 
after treatment in a clinical case series and significantly 
better outcomes in the treatment group compared to a 
nontreatment group in a prospective randomized study 
 [19] . However, due to the prototype character of this laser 
method, treatment numbers are still low and, addition-
ally, we do not know whether chronic-recurrent CSC cas-
es also benefit from SRT.
 In this consecutive case series, we applied SRT in both 
acute and chronic-recurrent types of CSC to evaluate the 
clinical responses. To further reduce the necessary energy 
to induce RPE cell damage and, thus, reduce potential 
heat generation in the sensitive tissue of the fovea  [14] ,  we 
tested and compared the established 1.7-μs with 300-ns 
pulse durations. 
 We were aware of the fact that, during recent years, 
half-dose photodynamic treatment (PDT) was found to 
be effective in chronic cases. A meta-analysis by Ma et al. 
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 [20] summarized results on 319 cases from 9 reports 
showing the best benefits for patients after PDT rather 
than after conventional focal laser or even anti-VEGF 
treatment. PDT therefore should be considered as the 
first-choice treatment in those cases. Therefore – derived 
from baseline angiographic findings – we tried mainly to 
focus on specific chronic-recurrent cases with ‘clear’ leak-
age areas. Such patients may eventually also profit from 
SRT in spite of being ‘chronic’ without the need for inva-
sive and expensive PDT.
 Material and Methods 
 Preliminary Remark 
 In this highly experimental study, the first prototype laser for 
SRT was used in a clinical setting. To date, no SRT laser is com-
mercially available; thus, overall experience with SRT is very lim-
ited, and only 3 more machines have been built. By collecting clin-
ical experience with our prototype, laser parameters and the laser 
delivery system have been adjusted and modified over years. 
Moreover, due to the fact that the first author moved twice during 
recent years, this paper reveals the ‘collected’ results from two sites 
over a time span of several years because of new installations, mod-
ifications and ethical approvals in Switzerland. However, a consid-
erable number of patients have been treated with this feasible 
method; thus, for us it is worthy to share these promising results 
with the ophthalmologic society.
 Patients and Examinations 
 Twenty-six patients with active acute (n = 10) or active chron-
ic (n = 16) CSC were included in this two-center study. Twenty-
one patients were treated at the University Eye Hospital in Regens-
burg, Germany, and 5 patients at the University Eye Hospital (In-
selspital) in Bern, Switzerland. The study was approved by the
local ethics committees and registered at www.clinicaltrials.gov
as NCT00403884 (Regensburg site) and as NCT02088151 (Bern 
site). 
 Complete ophthalmologic examination, including ETDRS vi-
sual acuity, slit-lamp evaluation, indirect stereoscopic ophthalmos-
copy after pupil dilation, FA and autofluorescence (Heidelberg Ret-
ina Angiograph HRA 2, Heidelberg Engineering GmbH, Germany) 
as well as SD-OCT imaging (Spectralis-OCT, Heidelberg Engineer-
ing) were undertaken before treatment and during the follow-up at 
4 weeks and 3 months (and individually longer, if necessary, due to 
re-treatments) after SRT. Formation of choroidal neovasculariza-
tion was ruled out in every case by FA and SD-OCT imaging. Fur-
ther exclusion criteria for SRT were other retinal and macular dis-
eases, prior macular and retinal treatments, such as laser, cryoco-
agulation or vitrectomy, as well as decompensated glaucoma.
 Active CSC was identified by SRF in the foveal area as judged 
by SD-OCT before treatment. Acute CSC was defined by active fo-
cal leakage in FA and/or duration <3 months. Chronic-recurrent 
CSC was defined by a mottled appearance of RPE in FA with one 
or more spots of fluorescein leakage, which could be aimed at with 
laser, and/or a duration of SRF for more than 3 months. Irregular 
patterns of increased autofluorescence were also frequently ob-
served in these patients  [21] . If no clinical success was obtained 
within 3 months after initial treatment, SRT re-treatment was con-
sidered and individually followed up. 
 Laser and Settings 
 A clinical prototype SRT laser system (SRT vario; Medical La-
ser Center Lübeck GmbH, Lübeck, Germany), as described in 
more detail elsewhere  [15] , was used in this study. Briefly, the laser 
consists of a diode laser excited Q-switched Nd:YLF laser that gen-
erates a wavelength of 527 nm by intracavity frequency conversion. 
The duration of the Q-switched pulse can be adjusted from 200 ns 
to 3 μs by increasing the efficiency of the second harmonic gen-
eration into the overcoupling regime  [22] . The laser was always 
operated at a repetition rate of 100 Hz and a train of 30 pulses was 
always delivered to each retinal spot. The maximal pulse energy of 
the laser system was 1 mJ. Five patients were treated with 1.7-μs 
pulse duration; this is the pulse duration originally used with SRT 
 [23] . For most patients in this study, the pulse duration was re-
duced to about 300 ns since less laser energy is required for RPE 
cell disruption and, thus, less overall heat is produced  [15, 23] .
 The laser light was coupled with an optical fiber either into an 
ophthalmic laser slit lamp (SL/L 30, Carl Zeiss Meditec AG, Jena, 
Germany) or into a scanning digital ophthalmoscope (SDO) (Wild 
GmbH, Völkermarkt, Austria). All Regensburg patients and the 
first Bern patient were treated with the slit lamp setup. The remain-
ing 4 Bern patients received treatment with the SDO. 
 In both treatment devices, the emitted pulse energy was re-
stricted to 400 μJ (1.7 μs) and 200 μJ (300 ns), respectively. A red 
diode laser beam (635 nm) served as the aiming light.
 In the slit lamp setup, the fiber tip was imaged onto the fundus 
with an ophthalmoscopic contact lens (Mainster, OMRA-S), gen-
erating a retinal spot size of 200 μm. An ultrasonic transducer 
(Medical Laser Center Lübeck) was integrated in order to detect 
microbubble formation, which is the origin of selective RPE cell 
damage  [24] . This optoacoustic device enabled the detection of the 
desired RPE cell damage for the ophthalmoscopically invisible 
SRT laser lesions in real time during treatment  [12, 25] .  Figure 1 a 
shows the setting of the laser, the slit lamp and the optoacoustic 
device connected to the recording PC.
 Since an SDO projects the laser beam onto the retina without 
the need of a contact lens, the feedback based on an ultrasonic 
transducer could not be used. Treatment monitoring instead was 
conducted using an external monitor and the live video derived 
from the SDO. Herein, aiming and treatment was guided by the 
live video image on the TV screen ( fig. 1 b).
 Treatment and Dosimetry 
 Since human fundus pigmentation may vary among individu-
als and even within the fundus of 1 patient by a factor of two  [26] 
or more, and the fact that the SRT lesions are ophthalmoscopi-
cally invisible, the cell damage energy needs to be adjusted for each 
patient. To this end, 5–10 test exposures were delivered at the low-
er vessel arcade and simultaneously recorded by optoacoustic 
measurements in each patient. The laser energy was increased un-
til lesions became ophthalmoscopically visible, which occurs typi-
cally at twice the angiographic threshold, or until maximal laser 
energy was reached. FA was performed 1 h after this dosimetry 
measurement to determine the individual threshold energy for an-
giographic visibility. In FA for SRT dosimetry, focal leakage be-
comes visible in the test spots when the laser has damaged RPE 
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cells and thereby compromised the integrity of the outer blood 
retinal barrier. Thus, absence of fluorescein leakage in the test 
spots indicates insufficient laser energy that is unable to damage 
RPE, i.e. the laser energy is below threshold. When the energy is 
too high, FA leakage along with increased light scattering in the 
test spot that resembles lesions generated by conventional laser 
photocoagulation most likely indicates adverse neuroretinal tissue 
damage (ophthalmoscopic threshold). The desired selective RPE 
damage is obtained when fluorescein leakage in the absence of 
ophthalmoscopic visibility is obtained (angiographic threshold).
 The treatment energy was chosen slightly above the detected 
angiographic threshold but well below the ophthalmoscopic 
threshold to avoid the risk of central neuroretinal damage with an 
adequate safety margin. 
 Immediately after threshold determination, SRT energy was 
aimed at the CSC leakage points and/or the area of leakage. One 
hour after SRT, a second FA was performed to confirm that desired 
RPE damage was obtained. Re-treatment with SRT (re-SRT) was 
performed the same day with sufficient laser energy.
SRT laser setup
SRT laser
Laser slit lamp
PC with optoacoustic
detection unit
a
b
 Fig. 1.  a The setting of the prototype SRT 
laser built by the Laser Center Lübeck, Ger-
many, with the laser slit lamp and the op-
toacoustic detection device connected to 
the recording PC.  b The SDO setting. The 
physician treats the macular area by using 
the monitor image for aiming instead of the 
direct slit lamp setup. 
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 Results 
 Acute CSC 
 We treated 10 eyes of 10 patients with active acute CSC 
as characterized by pinpoint (PP) leakage and persistent 
SRF detected by OCT. The median age of the patients was 
44 years (range 37–56 years). The mean baseline visual 
acuity was 76.6 ETDRS letters (range 72–90). All SRT 
treatments were performed without significant complica-
tions. Most importantly, no patient complained of central 
microscotoma after SRT. Five to eight treatment lesions 
were placed for treatment (median 6). The first 2 patients 
in Regensburg were treated with pulses of 1,700 ns, the 
other ones with pulses of 300 ns. Treatment energy with 
1,700 ns was about 200 μJ. Energy was decreased by a fac-
tor of 1.5 when switching to 300-ns pulses (100–160 μJ). 
All SRT lesions were clinically invisible, with the excep-
tion of 1 patient. That patient was treated with 300 ns and 
pulse energy of 160 μJ in Bern. Small hemorrhage oc-
curred at the laser site of two lesions but stopped sponta-
neously; thus, no further intervention was needed. Hem-
orrhages were resolved completely in the 3-month fol-
low-up, and visual acuity increased from 73 to 79 ETDRS 
letters. FA visualized the SRT lesions in all patients about 
1 h after SRT, confirming the desired cell damage effect. 
Thus, no immediate re-SRT was necessary. 
 SRF had completely resolved after SRT in 5 of the 10 
patients after 4 weeks and in all 10 patients after 3 months. 
The mean visual acuity increased from 76.6 to 77.9 (4 
weeks) and finally to 85.0 ETDRS letters at 3 months.
 FA was performed at the Regensburg site at each fol-
low-up visit (n = 5). No fluorescein leakage was observed 
 Table 1.  Results of SRT in acute CSC, part 1
Case
No.
Age,
years 
Type of
leakage
Duration of single 
laser pulse, ns
Treatment
energy, μJ
Laser spots, 
n
Lens
status
SRF finally
resolved?
2 39 pinpoint 1,700 200 5 clear yes
5 47 pinpoint 1,700 200 5 clear yes
6 37 pinpoint 300 100 6 clear yes
10 44 pinpoint 300 160 5 clear yes
13 50 pinpoint 300 120 5 clear yes
B1 47 pinpoint 300 100 8 clear yes
B2 44 pinpoint 300 120 7 clear yes
B3 41 pinpoint 300 140 8 clear yes
B4 56 pinpoint 300 120 20 clear yes
B5 42 pinpoint 300 180 7 clear yes
 Table 2. Results of SRT in acute CSC, part 2
Case 
No.
VA SRF  FA
baseline 4 weeks 3 months baseline 4 weeks 3 months  baseline 4 weeks 3 months
2 90 80 95 1 0 0 1 0 0
5 75 80 95 1 0 0 1 0 0
6 75 75 75 1 1 0 1 1 0
10 70 80 75 1 1 0 1 1 0
13 80 75 95 1 0 0 1 0 0
B1 73 74 79 1 1 0 1 – –
B2 84 79 84 1 1 0 1 – –
B3 74 80 89 1 1 0 1 – –
B4 72 78 79 1 0 0 1 – –
B5 73 78 84 1 1 0 1 – –
VA = Visual acuity (ETDRS letters); 1 = present; 0 = not present.
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in patients with resolved SRF. One of the 2 patients with 
persistent SRF after 4 weeks showed no SRF and no leak-
age after 3 months. In the second follow-up after 3 months, 
fluorescein leakage had ceased in all patients. All results 
for acute CSC are displayed in  tables 1 and  2 . A typical 
course of SRT in acute CSC is shown in  figure 2 .
 Chronic CSC 
 Sixteen eyes of 16 patients with active chronic CSC 
were treated. All patients showed PP leakage and/or dif-
fuse leakage in FA and persistent SRF judged by OCT. FA 
leakage was considerably less than in acute CSC,  and sub-
retinal precipitates were observed on a regular basis, in-
dicating chronic disease. All 16 patients were male. The 
median age of the patients was 52 years (range 41–65 
years). The baseline visual acuity was 71.6 ETDRS letters. 
All SRT treatments were performed without any compli-
cations. The median number of treatment lesions was 7 
(range 3–14). The first 3 patients were treated with pulses 
of 1,700 ns, after reducing the pulse duration of the laser 
unit, the other 13 patients underwent SRT with pulses of 
300 ns. The treatment energy of the first 3 patients was 
between 200 and 250 μJ; the treatment energy of the oth-
er 13 patients with 300 ns was 100–180 μJ. None of the 
SRT lesions was clinically visible. FA was performed to 
visualize the SRT lesions in nearly all of the patients 1 h 
after SRT. No patient complained of central microscoto-
ma after SRT. 
a
FA before treatment
Focal point
of leakage
SD-OCT before treatment
200 μm200 μm
Treatment
area
Test lesions with
increasing energies
FA 1 h after treatment
Baseline SD-OCT
SD-OCT 3 months after SRT
b
 Fig. 2. Course of acute CSC treated with 
SRT.  a FA before and after treatment and 
preoperative SD-OCT scan revealing SRF. 
 b Three months after treatment, the SRF 
completely resolved. External limiting 
membrane is intact, indicating good visual 
acuity recovery. 
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 The follow-up after 4 weeks showed an absence of SRF 
in SD-OCT in 2 of 14 patients, while lack of fluorescein 
leakage on FA was observed in 5 of 14 patients (2 patients 
were missed at week 4). The mean visual acuity changed 
from baseline 71.6 to 72.8 ETDRS letters after 3 months 
(70.9 letters after 4 weeks). After 3 months, SRF had re-
solved in 3 out of 16 patients (19%), whereas a complete 
stop of leakage activity in FA was observed in 6 out of 16 
patients (38%).  Tables 3 and  4 give detailed information 
on the individual courses, on which some were recom-
mended to receive PDT. 
 In 6 out of these 16 patients with chronic CSC, a second 
SRT with higher energy levels was performed because of 
persistent leakage activity in FA in addition to residual 
SRF.  After re-treatment with SRT, the SRF was resolved in 
5 of these 6 patients after a median time of 25 days (range 
21–35 days). The mean visual acuity increased slightly 
from 71.7 to 72.5 ETDRS letters at 3 months (74.2 letters 
at 4 weeks). After 4 weeks, we observed no SRF in 4 of 6 
patients and nearly resolved SRF in 1 patient; the reduc-
tion in SRF was accompanied by no leakage on FA in 4 of 
6 patients. At the 3-month follow-up, we found resolved 
SRF in 5 and absence of leakage in 4 out of 6 patients. One 
patient with persistent SRF and leakage in FA was recom-
mended for PDT. The results for re-SRT in chronic-recur-
rent CSC are displayed in  tables 5 and  6 . A typical course 
of re-SRT in chronic-recurrent CSC is shown in  figure 3 . 
 Discussion 
 CSC mainly affects young, working-age males and re-
sults in moderate-to-severe disturbances of vision. Al-
though the disease frequently resolves spontaneously, the 
commonly used ‘wait and see’ approach may be question-
able since these patients usually stay in their jobs and 
work on a daily basis. Because conventional laser photo-
coagulation leads to faster resolution but also results in 
central laser scars and blind spots  [27, 28] , waiting for 
self-improvement is justified. However, the novel laser 
treatment SRT selectively treats the RPE without harming 
the photoreceptors. It stabilizes the RPE layer and leads 
to enhanced pump function and fast resolution of the SRF 
 [17–19] and, thus,  offers  a viable therapeutic approach for 
CSC. Selectivity of the SRT technique could be proven 
experimentally  [12, 13] and clinically by microperimetric 
studies  [25] . Moreover, a recent SD-OCT study in SRT 
laser lesions was also able to show the noncoagulating 
character of this laser technique in human eyes  [29] .
 Until SRT becomes commercially available, one might 
consider medical treatment of CSC in acute and maybe 
also chronic cases. Since no ‘gold standard’ for the treat-
ment of CSC is available yet, review articles and case se-
ries until 2012 suggest carbonic anhydrase, mild laser 
photocoagulation, SRT and PDT as well as intravitreal 
injections of bevacizumab, showing heterogeneous re-
 Table 3. Results of first SRT in chronic CSC, part 1
Case 
No.
Age,
years
Type of
leakage
Duration of single
laser pulse, ns
Treatment
energy, μJ
Laser spots, n Lens
status
SRF
resolved?
1 46 2× old PP 1,700 250 4 clear yes
3 55 2× old PP 1,700 200 9 clear yes
4 40 PP + diffuse 1,700 200 4 clear yes
7 49 PP + diffuse 300 120 3 clear no
9 50 diffuse 300 140 4 clear yes
12 41 diffuse 300 160 5 clear no
16 54 PP + diffuse 300 140 4 inc. no
19 47 diffuse 300 120 – 180 12 clear yes
20 58 diffuse 300 120 – 160 12 clear yes
21 51 PP + diffuse 300 120 – 140 14 inc. no
8 54 2× PP 300 100 7 inc. re-SRT
11 48 diffuse 300 120 6 clear re-SRT
14 54 diffuse 300 120 7 inc. re-SRT
15 48 PP + diffuse 300 140 6 clear re-SRT
17 65 diffuse 300 140 – 160 8 clear re-SRT
18 64 diffuse 300 200 8 cat. re-SRT
Data are displayed for consecutive cases and cases in need of re-SRT. inc. = Incipient cataract formation; 
cat. = moderate cataract formation. 
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 Table 4. Results of first SRT in chronic CSC, part 2
Case 
No.
VA SRF FA Remarks
baseline 4 weeks 3 months baseline 4 weeks 3 months baseline 4 weeks 3 months
1 95 95 95 1 1 1 1 1 0 A
3 70 65 65 1 – 0 1 – 0
4 40 40 45 1 0 0 1 0 0
7 60 60 60 1 1 1 1 1 1 B
9 70 70 70 1 1 1 1 1 1 C
12 75 75 80 1 1 1 1 0 0 D
16 75 75 75 1 1 1 1 1 1 E
19 75 75 90 1 1 0 1 0 0
20 80 80 90 1 0 1 1 0 1 F
21 75 80 75 1 1 1 1 1 1 G
8 80 80 80 1 1 – 1 1 –
11 70 75 75 1 1 1 1 1 1
14 70 60 65 1 1 1 1 1 1
15 75 70 65 1 1 1 1 1 1
17 80 80 80 1 1 1 1 1 1
18 55 55 55 1 – 1 1 – 1
VA = Visual acuity (ETDRS letters); 1 = present; 2 = not present; A = after 6 months: no SRF and no leakage in FA; B = new leakage 
points, PDT recommended; C = new leakage point; D = decreased SRF, but no further control visit; E = PDT for chronic CSC, later 
bevacizumab for occult choroidal neovascularization; F = new leakage point after 3 months; G = new leakage points, PDT recommended.
 Table 5. Results of re-SRT in chronic CSC, part 1
Case
No.
Age,
years
Months
after first SRT
Type of
leakage
Duration of single 
laser pulse, ns
Treatment
energy, μJ
Laser
spots, n
Lens
status
Day at which 
SRF resolved 
8 54 1 diffuse 300 120 4 clear 21
11 48 3 diffuse 300 140 6 clear 35
14 54 5 diffuse 300 140 7 inc. no
15 48 3 PP + diffuse 300 180 8 clear 21
17 65 3 diffuse 300 160 7 inc. 27
18 64 4 diffuse 300 290 11 cat. 23
inc. = Incipient cataract formation; cat. = moderate cataract formation.
 Table 6. Results of re-SRT in chronic CSC, part 2
Case
No.
VA SRF FA Re-
marksbaseline 4 weeks 3 months baseline 4 weeks 3 months baseline 4 weeks 3 months
8 80 90 90 1 0 – 1 0 –
11 70 80 80 1 0 – 1 0 –
14 70 70 70 1 1 1 0 0 0 H
15 75 70 65 1 0 0 1 0 0
17 80 75 70 1 0 0 1 0 0
18 55 60 60 1 0 0 1 1 1 J
In cases 8 and 11, VA at 3 months was the last observation carried forward. VA = Visual acuity (ETDRS letters); 1 = present; 2 = not 
present; H = PDT recommended (persistent SRF, diffuse leakage point); J = SRT with maximal energy because of posterior subcapsular 
cataract, 5 months later cataract surgery in combination with intravitreal bevacizumab injection for occult choroidal neovascularization. 
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sults  [30–32] . However, since it is known that glucocorti-
coids induce and aggravate CSC and are known to bind 
to the mineralocorticoid receptor, a blockade of these re-
ceptors might be of benefit in treating this disease with
a specific mineralocorticoid receptor antagonist as spi-
ronolactone  [33] . This beneficial effect could be demon-
strated by a significant reduction of central macular 
thickness, SRF level, and an improvement in visual acuity 
 [34] . However, the effect might be difficult to distinguish 
from the spontaneous course  [35] . SRT might have the 
potential to overcome all described treatment options; 
however, this needs to be proven in direct comparative 
trials.
 The clinical value of SRT in acute CSC has already 
been demonstrated in 2 different studies showing com-
plete resolution of SRF in 85.2% of 27 patients within 4 
weeks and a 100% resolution rate 3 months after irradia-
tion  [18] . The authors recommended early treatment in 
acute CSC using SRT  [18] since neither visible coagula-
tion nor complications occurred and the SRF resolved 
quickly after treatment. To confirm the benefit of SRT in 
active acute CSC, the same authors designed a prospec-
tive randomized trial and recruited 30 patients, from 
whom 14 eyes received SRT and 16 eyes served as control. 
Significantly better improvement of best corrected visual 
acuity (BCVA) of 12.7 ETDRS letters was observed in the 
laser group versus 6.3 letters in the control group and also 
SRF thickness decreased more significantly (203 vs. 41 
μm)  [19] . Eight eyes of the control group without BCVA 
increase within 3 months were then crossed over to the 
SRT group, and again significant BCVA increase (7.4
ETDRS letters) and SRF reduction (151.5 μm) were no-
ticed after treatment  [19] . 
 Based on these results, SRT appears to be an interest-
ing therapeutic option for the treatment of acute CSC. 
However, CSC presents very heterogeneously. While 
a b c
d e f
g h i
 Fig. 3. Course of chronic-recurrent CSC treated with SRT and re-
SRT.  a  At baseline, the fundus photograph revealed central pig-
ment alterations indicating chronic CSC.  b FA showed diffuse mot-
tling and two PP leakages in the macular area.  c In SD-OCT, SRF 
as well as subretinal precipitates were seen.  d  Three months after 
first SRT no clinical improvement was observed. No laser lesions 
around the PP leakages were seen on the fundus photograph. Test 
lesions at the lower arcade could be noticed by slight hyperfluores-
cent spots. Some central leakage was still seen ( e ), and SD-OCT 
revealed the same amount of SRF as before SRT ( f ). Four weeks 
after the second SRT using higher energy levels, laser lesions were 
still ophthalmoscopically invisible ( g ), but FA showed no leakage 
( h ), and the corresponding SD-OCT revealed completely dry reti-
nal conditions and even an intact external limiting membrane ( i ). 
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many acute cases resolve spontaneously, CSC can mani-
fest as a chronic or chronic-recurrent condition. Our 
main interest in this study was the evaluation of the first 
use of 300-ns laser pulses in CSC and the disease response 
of the chronic and chronic-recurrent forms of CSC to 
SRT. 
 Our results confirm a favorable course of acute CSC 
after SRT showing no SRF in all cases after 3 months. This 
is comparable with the results of Roider and coworkers 
 [18] ; however, our rate of complete SRF resolution was 
lower after 4 weeks (40%). One explanation might be the 
use of SD-OCT in our study in contrast to the OCT3 used 
in the cited study  [18] . Modern SD-OCT affords higher 
axial resolution enabling the detection of very small re-
sidual SRF accumulations. Since even small residual SRF 
was judged as ‘non-resolution’ in our patients, a seem-
ingly lower success rate may have been obtained if the 
older OCT 3 had missed residual SRF accumulations. 
 In chronic-recurrent CSC, diffuse hyperfluorescence 
with one or more PP lesions and progressive but weaker 
leakage is usually observed in FA. The RPE seems to be 
diffusely altered, which can be detected mainly by auto-
fluorescence  [21] . Since RPE barrier integrity in CSC 
seems to arise secondary to choroidal hyperpermeability 
 [36] , today photodynamic therapy (PDT) using full or 
half doses is often recommended on an ‘off-label basis’ in 
these cases  [37, 38] . We test here if SRT can be a nonin-
vasive and cheap alternative to PDT. SRT does not re-
quire the injection of a photoactive drug, and light expo-
sure is confined to small irradiation spots that avoid the 
irradiation of the entire fundus. While an SRT therapeu-
tic effect on the choriocapillary layer has not been dem-
onstrated so far, but broad damage to it as with PDT is 
supposed to be avoided, the proof-of-principle for SRT 
therapeutic benefit in CSC is clearly given by Roider’s 
group  [18, 19] .
 We treated 16 patients with chronic-recurrent CSC to 
find out whether SRT might be helpful even in these cas-
es. No adverse events were noted, and all laser lesions 
were ophthalmoscopically invisible. As expected, the 
BCVA and OCT results were worse than those of acute 
forms. No SRF resolution was observable in 10 out of 16 
patients (62.5%) after 3 months. In those eyes with com-
plete resolution, half of the eyes (n = 3) needed longer 
than 3 months ( table 3 ).
 Six patients with unsatisfying SRT outcomes were 
asked to undergo a second SRT treatment. While laser 
energy was adjusted above the initial levels, treatment 
within the therapeutic window between the angiographic 
and ophthalmoscopic threshold was always ensured. In-
terestingly, after re-SRT, SRF had disappeared complete-
ly within only 4 weeks in all but 1 patient ( table 6 ). For the 
patient with no SRF resolution, PDT was recommended. 
Thus, SRT can also be effective in chronic-recurrent CSC, 
when treatment is repeated after potential initial treat-
ment failure. Most likely, this effect is not due to increased 
pulse energy since the re-treatment still selectively targets 
RPE cells. More likely is the explanation that this method 
involves repeated stimulation at different time points; 
however, the exact mechanism is unknown. 
 Although the number of patients was small and the 
study not controlled, the long-lasting presence of SRF in 
these patients was impressively resolved within a very 
short time after re-SRT in spite of the previous treatment 
failure. While we conclude from this observation that the 
therapeutic response was in fact SRT derived, we also see 
the need to further investigate the efficacy and mecha-
nism of this treatment. A prospective controlled study 
comparing PDT with SRT in chronic-recurrent CSC as 
determined, for example, by preoperative autofluores-
cence and chronic SRF in SD-OCT is worth considering. 
Such study could investigate the influence of parameters, 
such as the number of laser lesions, the density of the le-
sions, pulse energy as well as the number and best time 
points of re-treatments, on the efficiency of the treatment.
 Since, especially in acute forms, treatment effects 
should be superior to the spontaneous course, which in 
principle has been already shown by Roider and co-work-
ers  [19] , one might ask when an improvement can be ex-
pected following treatment. In all studies, earliest visits 
were performed 4 weeks postoperatively. However, since 
RPE regeneration regularly takes place within the 1st 
week after irradiation  [8–10] , clinical improvement might 
be expected within the 2nd week. In detail, this should be 
examined in a larger CSC trial. The best monitoring tool 
for such examinations is SD-OCT, whereas FA is sup-
posed to be of less importance in clinical routine  [39] .
 With respect to the two pulse durations used, we found 
that only 67% of the pulse energy is needed for 300 ns in 
comparison to 1.7 μs to obtain the desired RPE damage, 
as demonstrated by FA leakage. This outcome corre-
sponds well with experimental findings on RPE cells  [14] 
 and with first clinical trials  [15] . With respect to chronic 
CSC, it is notable, although not statistically significant, 
that SRF resolved in all the 3 patients treated with 1.7-μs 
pulses, while those patients with no improvement in SRF 
after 3 months were treated with 300 ns. 
 With respect to the different delivery setup in the 
study, i.e. once with a slit lamp and once with an SDO, no 
significant differences could be found despite the missing 
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stereoscopic visualization with the SDO. However, in 
some cases the operator noticed moderate video quality 
of the SDO. For the clinical outcome, no significant dis-
advantages have been observed . 
 A great benefit of the SRT technique is the virtual non-
existence of intraoperative complications afforded by the 
selective nature of the microsecond pulses that minimize 
heat diffusion into neurosensory tissue. In this study, 
complications occurred in only 1 patient, which is in ac-
cordance with the other SRT studies  [18, 19] . Here, we 
noted the first exception when two small laser-induced 
hemorrhages appeared in the 1st patient in Bern. This oc-
curred after the laser pulse duration was switched to 300 
ns and much lower laser thresholds resulted. The patient 
did not notice any scotoma, and visual acuity improved 
during follow-up. The bleeding was most likely due to the 
slightly more explosive microvaporization at the different 
melanosomes from nanosecond pulses, which leads to 
larger coalescing bubbles than those resulting from the 
more timely deferred vaporization with microsecond 
pulses  [40] . However, the basic reason for two small hem-
orrhages is unclear. Due to the fact that many patients 
were treated with pulse energies around 160 μJ and 300-
ns pulse duration without any adverse effects, maybe a 
local hyperpigmentation in combination with an adja-
cent small vessel accounted for this effect.
 Selective RPE damage can only be achieved with short 
microsecond pulses. Most of the other ‘so-called’ micro-
pulse techniques are not able to confine the damage to the 
RPE and to completely avoid laser scotoma since they de-
liver pulses as, for example, 100 μs. RPE cells are damaged 
thermomechanically by the formation of microbubbles 
by nanosecond and short microsecond pulses, while ther-
mal damage, that is, coagulation, is observed with pulses 
of a few milliseconds and longer. The transition of pho-
todisruption to photothermal denaturation occurs at ex-
posure durations between 20 and 50 μs  [41, 42] .  With 
SRT, axial and lateral heating of the tissue is confined to 
the absorbing RPE cells, whereas conventional photoco-
agulation is associated with strong heat diffusion into the 
neural retina and choroid with subsequent scotoma and 
scar formation. Therefore, selectivity with the sparing of 
photoreceptors is the most important benefit in laser-
treated CSC because RPE leakage points are usually lo-
cated near to the fovea, where classic laser coagulation 
should be avoided. Hence, SRT seems to be the appropri-
ate laser technique.
 In conclusion, SRT seems to be a valuable tool for ear-
ly first-line treatment of acute CSC and maybe also in 
chronic-recurrent CSC. No adverse side effects are ex-
pected in a routinely used and commercially available la-
ser system.
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